Showing 661-670 of 2150 results for "".
- Possible Treatment for Focal Laryngeal Dystonia Revealed at MDS Conferencehttps://practicalneurology.com/news/possible-treatment-for-focal-laryngeal-dystonia-reported-at-mds-conference/2470597/Results of a double-blind, placebo-controlled, randomized cross-over study presented at the 2024 International Congress of Parkinson’s Disease and Movement Disorders suggest that sodium oxybate (SO) may be an effective treatment for some people with focal laryngeal dystonia (LD). This phase
- In Memoriam: Ralph L. Sacco, MD, MS, FAHA, FAANhttps://practicalneurology.com/news/in-memoriam-ralph-l-sacco-md-ms-faha-faan/2470102/
- Barancik Prize Awarded to Dr. Ruth Ann Marrie at ACTRIMS 2023https://practicalneurology.com/news/barancik-prize-awarded-to-dr-ruth-ann-marrie-at-actrims-2023/2470120/The National Multiple Sclerosis Society announced that Ruth Ann Marrie, MD, P
- Fenfluramine May Usher in Higher Standards for Treatment of Dravet Syndromehttps://practicalneurology.com/news/fenfluramine-may-usher-in-higher-standards-for-treatment-of-dravet-syndrome/2469642/In an editorial in Epilepsy and Behavior, Helen Cross, MD and Joseph Sullivan, MD suggest fenfluramine (Fintepla; Zogenix, Emeryville, CA) clinical trial results can raise the bar for efficacy of antiseizure medications (ASMs) for
- Pitolisant Clinical Trial for Type 1 Myotonic Dystrophy Excessive Daytime Sleepinesshttps://practicalneurology.com/news/pitolisant-clinical-trial-for-type-1-myotonic-dystrophy-excessive-daytime-sleepiness/2469633/A phase 2 clinical trial (NCT04886518) for pitolisant (Wakix; Harmony Biosciences, Plymouth Meeting, PA) in adults with type 1 myotonic dystrophy (DM1) experiencing excessive daytime sleepiness (E
- Azeliragon Studies for Treatment of Alzheimer Disease In People With Type II Diabetes Continuehttps://practicalneurology.com/news/azeliragon-studies-for-treatment-of-alzheimer-disease-in-people-with-type-ii-diabetes-continue/2469421/Baseline characteristics for participants enrolled in a phase 2/3 study, Elevage (NCT03980730), of azeliragon (vTv Therapeutics, High Point, NC) for mild Alzheimer disease (AD) in people with type 2 diabetes have been reported. In an e
- Vatiquinone Proceeds to Phase 2/3 Studies for Treatment of Mitochondrial Epilepsyhttps://practicalneurology.com/news/vatiquinone-proceeds-to-phase-23-studies-for-treatment-of-mitochondrial-epilepsy/2469409/A registration-directed phase 2/3 clinical trial (NCT04378075) to evaluate vatiquinone (PTC743; PTC Therapeutics, South Plainfield, NJ) in individuals with mitochondrial epilepsy (MIT-E) has begun
- Award Recipients Recognized at the 2024 International Congress of Parkinson’s Disease and Movement Disordershttps://practicalneurology.com/news/award-recipients-recognized-at-the-2024-international-congress-of-parkinsons-disease-and-movement-disorders/2470598/The International Parkinson’s Disease and Movement Disorders Society (MDS) has announced recipients of the 2024 MDS Awards. The awards honor professionals in the field who are elevating care for movement disorders through their contributions to research, scholarship, and clinical work. The
- FDA Approves Mirabegron for Neurogenic Detrusor Overactivity in Pediatric Patientshttps://practicalneurology.com/news/fda-approves-mirabegron-for-neurogenic-detrusor-overactivity-in-pediatric-patients/2469543/The Food and Drug Administration approved a new indication for mirabegron extended-release tablets (Myrbetriq; Silver Spring, MD) and mirabegron for extended-release oral suspension (Myrbetriq Granules; Silver Spring, MD) to treat neurogenic detrusor overactivity (NDO) in children age 3 yea
- New Titration Schedule for Kisunla/Donanemab Approved by FDAhttps://practicalneurology.com/news/new-titration-schedule-for-kisunladonanemab-approved-by-fda/2475633/The Food and Drug Administration (FDA) has approved a new titration dosing schedule for Kisunla (donanemab-azbt; Eli Lilly and Company, Indianapolis, IN), which is intended to lower the risk of amyloid-related imaging abnormalities with edema/effusion (ARIA-E) in the treatment of people with earl